Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 316965, 6 pages
http://dx.doi.org/10.1155/2015/316965
Research Article

The Effects of Bromocriptine on Preventing Postpartum Flare in Systemic Lupus Erythematosus Patients from South China

Department of Rheumatology & Clinical Immunology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, China

Received 27 September 2014; Revised 22 January 2015; Accepted 28 January 2015

Academic Editor: Marco Antonio Velasco-Velázquez

Copyright © 2015 Qiu Qian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Stojan and A. N. Baer, “Flares of systemic lupus erythematosus during pregnancy and the puerperium: prevention, diagnosis and management,” Expert Review of Clinical Immunology, vol. 8, no. 5, pp. 439–453, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Liu, Y. Zhao, Y. Song et al., “Pregnancy in women with systemic lupus erythematosus: a retrospective study of 111 pregnancies in Chinese women,” Journal of Maternal-Fetal and Neonatal Medicine, vol. 25, no. 3, pp. 261–266, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. X. Yang and P. Yin, “Prolactin and autoimmune diseases,” Chinese Journal of Internal Medicine, vol. 35, no. 1, pp. 60–62, 1996 (Chinese). View at Google Scholar · View at Scopus
  4. M. Zen, A. Ghirardello, L. Iaccarino et al., “Hormones, immune response, and pregnancy in healthy women and SLE patients,” Swiss Medical Weekly, vol. 140, no. 13-14, pp. 187–201, 2010. View at Google Scholar · View at Scopus
  5. S. E. Walker, R. W. Mcmurray, J. M. Houri et al., “Effects of prolactin in stimulating disease activity in systemic lupus erythematosus,” Annals of the New York Academy of Sciences, vol. 840, pp. 762–772, 1998. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Østensen, “Sex hormones and pregnancy in rheumatoid arthritis and systemic lupus erythematosus,” Annals of the New York Academy of Sciences, vol. 876, pp. 131–144, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Shelly, M. Boaz, and H. Orbach, “Prolactin and autoimmunity,” Autoimmunity Reviews, vol. 11, no. 6-7, pp. A465–A470, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. V. Legorreta-Haquet, R. Flores-Fernández, F. Blanco-Favela et al., “Prolactin levels correlate with abnormal B cell maturation in MRL and MRL/lpr mouse models of systemic lupus erythematosus-like disease,” Clinical and Developmental Immunology, vol. 2013, Article ID 287469, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Leaños-Miranda and G. Cárdenas-Mondragón, “Serum free prolactin concentrations in patients with systemic lupus erythematosus are associated with lupus activity,” Rheumatology, vol. 45, no. 1, pp. 97–101, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Neidhart, “Bromocriptine has little direct effect on murine lymphocytes, the immunomodulatory effect being mediated by the suppression of prolactin secretion,” Biomedicine and Pharmacotherapy, vol. 51, no. 3, pp. 118–125, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. K. B. Elbourne, D. Keisler, and R. W. McMurray, “Differential effects of estrogen and prolactin on autoimmune disease in the NZB/NZW F1 mouse model of systemic lupus erythematosus,” Lupus, vol. 7, no. 6, pp. 420–427, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. X.-Y. Yang, L.-Q. Liang, H.-S. Xu et al., “Efficacy of oral bromocriptine in protecting the postpartum systemic lupus erythematosus patients from disease relapse,” Chinese Journal of Internal Medicine, vol. 42, no. 9, pp. 621–624, 2003 (Chinese). View at Google Scholar · View at Scopus
  13. M. C. Hochberg, “Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 40, no. 9, article 1725, 1997. View at Google Scholar · View at Scopus
  14. C. Bombardier, D. D. Gladman, M. B. Urowitz et al., “Derivation of the SLEDAI: a disease activity index for lupus patients,” Arthritis and Rheumatism, vol. 35, no. 6, pp. 630–640, 1992. View at Publisher · View at Google Scholar · View at Scopus
  15. J. P. Buyon, M. A. Petri, M. Y. Kim et al., “The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial,” Annals of Internal Medicine, vol. 142, no. 12, part 1, pp. 953–962, 2005. View at Google Scholar · View at Scopus
  16. L. J. Jara, H. Pacheco-Reyes, G. Medina, U. Angeles, P. Cruz-Cruz, and M. A. Saavedra, “Prolactin levels are associated with lupus activity, lupus anticoagulant, and poor outcome in pregnancy,” Annals of the New York Academy of Sciences, vol. 1108, pp. 218–226, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Orbach, G. Zandman-Goddard, M. Boaz et al., “Prolactin and autoimmunity: hyperprolactinemia correlates with serositis and anemia in SLE patients,” Clinical Reviews in Allergy and Immunology, vol. 42, no. 2, pp. 189–198, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. O. Vera-Lastra, C. Mendez, L. J. Jara et al., “Correlation of prolactin serum concentrations with clinical activity and remission in patients with systemic lupus erythematosus. Effect of conventional treatment,” Journal of Rheumatology, vol. 30, no. 10, pp. 2140–2146, 2003. View at Google Scholar · View at Scopus
  19. G. Cárdenas-Mondragón, A. Ulloa-Aguirre, I. Isordia-Salas, V. Goffin, and A. Leaños-Miranda, “Elevated serum bioactive prolactin concentrations in patients with Systemic lupus erythematosus are associated with disease activity as disclosed by homologous receptor bioassays,” Journal of Rheumatology, vol. 34, no. 7, pp. 1514–1521, 2007. View at Google Scholar · View at Scopus
  20. A. Leaños-Miranda, K. A. Chávez-Rueda, and F. Blanco-Favela, “Biologic activity and plasma clearance of prolactin-IgG complex in patients with systemic lupus erythematosus,” Arthritis & Rheumatism, vol. 44, no. 4, pp. 866–875, 2001. View at Publisher · View at Google Scholar
  21. E. Peeva, J. Venkatesh, D. Michael, and B. Diamond, “Prolactin as a modulator of B cell function: implications for SLE,” Biomedicine and Pharmacotherapy, vol. 58, no. 5, pp. 310–319, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. R. W. McMurray, “Bromocriptine in rheumatic and autoimmune diseases,” Seminars in Arthritis and Rheumatism, vol. 31, no. 1, pp. 21–32, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. L. J. Jara, P. Cruz-Cruz, M. A. Saavedra et al., “Bromocriptine during pregnancy in systemic lupus erythematosus: a pilot clinical trial,” Annals of the New York Academy of Sciences, vol. 1110, pp. 297–304, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. A. M. Jacobi, W. Rohde, H.-D. Volk, T. Dörner, G.-R. Burmester, and F. Hiepe, “Prolactin enhances the in vitro production of IgG in peripheral blood mononuclear cells from patients with systemic lupus erythematosus but not from healthy controls,” Annals of the Rheumatic Diseases, vol. 60, no. 3, pp. 242–247, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Peeva, C. Grimaldi, L. Spatz, and B. Diamond, “Bromocriptine restores tolerance in estrogen-treated mice,” The Journal of Clinical Investigation, vol. 106, no. 11, pp. 1373–1379, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. M. E. Molitch, “Pituitary disorders during pregnancy,” Endocrinology and Metabolism Clinics of North America, vol. 35, no. 1, pp. 99–116, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Melmed, F. F. Casanueva, A. R. Hoffman et al., “Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 2, pp. 273–288, 2011. View at Publisher · View at Google Scholar · View at Scopus